Pharmafile Logo
Pharmafocus logo
Advanced Search

Medical Communications

Showing 15 posts of 6402 posts found.

figures_charts

Valeant’s ad hoc committee closes chapter on Philidor controversy

April 5, 2016 Medical Communications, Research and Development, Sales and Marketing Philidor, Valeant, ad hoc, ad hoc committee

Valeant (NYSE: VRX) has announced that the ad hoc committee of the board of directors has finished its review of …
News
pfizerbrussels

Pfizer’s tofacitinib shows promise for psoriatic arthritis treatment in Phase III trial

April 5, 2016 Medical Communications, Research and Development, Sales and Marketing Allergan, Pfizer, Xeljanz, merger, phase III, psoriatic arthritis, tofacitinib

Pfizer has announced positive top-line results from their latest Phase III study investigating Xeljanz (tofacitinib citrate). The OPAL Broaden trial …
News
stats_data

Timeline of turmoil – Valeant Pharmaceuticals’ troubled March 2016

April 4, 2016 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Share price, Valeant, fall, month from hell, timeline, turmoil

As far as months go, March 2016 couldn’t have gone much worse for Valeant Pharmaceuticals. The Canada-based company has been …
Feature
index_ph001

Daiichi Sankyo names Antoine Yver global head of oncology research and development

April 1, 2016 Business Services, Medical Communications Daiichi Sankyo, Japan, appointment

Japanese drug major Daiichi Sankyo (TYO: 4568) on Friday named Antoine Yver, global head, oncology research and development, effective April …
Appointment

FTC files complaint against Endo for blocking generics of its pain drugs

April 1, 2016 Business Services, Manufacturing and Production, Medical Communications, Sales and Marketing Endo International, FTC, legal, regulation

The US Federal Trade Commission (FTC) has filed a complaint against Endo International (Nasdaq: ENDP) alleging the company used illegal …
News
dynavax

FDA to review investigational hepatitis B vaccine

April 1, 2016 Medical Communications, Research and Development dynavax, hepatitis B, vaccines

Dynavax Technologies (NASDAQ: DVAX) says the FDA has accepted for review the company’s investigational adult hepatitis B vaccine, HEPLISAV-B. The FDA has set …
News

Whistleblower accuses Novartis of paying bribes in Turkey to push sales

April 1, 2016 Business Services, Medical Communications, Sales and Marketing Financial, Novartis, legal, reuters

An anonymous whistleblower has accused Swiss drugmaker Novartis (SIX: NOVN) of paying bribes in Turkey through a consulting firm to …
News
janssen_latest_logo_on_sign_closer

Janssen to stop fulranumab development in osteoarthritis pain

April 1, 2016 Medical Communications, Research and Development, Sales and Marketing Amgen, Janssen

Janssen says it is discontinuing Phase III development for fulranumab in osteoarthritis pain. The J&J company says the decision is …
News
pfizerbrussels

Fake press release on drug pricing “erroneously attributed” to Pfizer

April 1, 2016 Medical Communications Pfizer, fake, false, legal action, press release, washington post

Pfizer (NYSE: PFE) has issued a statement on a false press release related to drug pricing that was reported on …
News
fda

FDA releases biosimilars labelling guidance

April 1, 2016 Manufacturing and Production, Medical Communications, Research and Development FDA, biosimilars

The US Food and Drug Administration (FDA) has issued draft guidance on the labelling of biosimilar drugs. The guidance states …
News

Sanofi and Regeneron announce positive Phase III trial results for chronic skin disease treatment

April 1, 2016 Medical Communications, Research and Development Dupilumab, Regeneron, Sanofi, atopic dermatitis, phase III, skin disease

Sanofi (NYSE: SNY) and Regeneron Pharmaceuticals (NASDAQ: REGN) have announced positive top line results for dupilumab in Phase III clinical …
News
samsung_bioepis

Samsung Bioepis’ Remicade biosimilar set for CHMP verdict

March 31, 2016 Medical Communications, Sales and Marketing Flixabi, Remicade, Samsung Bioepis, biosimilars, infliximab

Samsung Bioepis has confirmed that the European Commission’s scientific committee, the CHMP, is this week discussing the approval of its …
News
valeant

Valeant’s outgoing CEO subpoenaed by US congressional committee

March 29, 2016 Medical Communications, Research and Development Drug pricing, Michael Pearson, US, Valeant, committee, pearson, pharma, price hikes, senate aging committee, subpoena, subpoenaed

The US Senate Aging Committee has announced the issuing of a subpoena to the outgoing CEO of Valeant Pharmaceuticals, Michael …
News
msd

MSD teams up with Harvard to develop new leukaemia treatments

March 24, 2016 Medical Communications, Research and Development AML, Harvard, MSD, leukaemia

MSD has entered a new collaboration with Harvard University aimed at developing innovative new small-molecule therapeutics for leukaemia and other …
News
novartis_pic

Novartis settles bribery charges in China for $25m

March 24, 2016 Medical Communications, Sales and Marketing Novartis

Novartis will pay $25 million to the US Government’s Securities and Exchange Commission to settle charges that it bribed healthcare …
News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025